Schering-Plough's Asmanex Clears FDA For Asthma
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of Asmanex will boost Schering's presence in the asthma therapy market, in which the company also markets Proventil HFA and Foradil. Schering's marketing for Asmanex is likely to focus on the product's dosing convenience.